Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And MoreSeeking Alpha · 1 day ago
Voyager Announces CEO Succession Plan, Appoints Robin Swartz PresidentGlobeNewsWire · 4 days ago
Voyager Therapeutics (NASDAQ:VYGR) Share Price Breaks Below 50 Day Moving Average – Here’s What HappenedDefense World · Oct 13, 2026
Tonix Pharmaceuticals (NASDAQ:TNXP) and Voyager Therapeutics (NASDAQ:VYGR) Critical ReviewDefense World · Sep 21, 2026
Aligos Therapeutics (NASDAQ:ALGS) & Voyager Therapeutics (NASDAQ:VYGR) Head-To-Head AnalysisDefense World · Sep 21, 2026
Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha · Sep 10, 2026Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.48 | -$0.40 | Beat |
| May 7, 2026 | -$0.54 | -$0.47 | Beat |
| Mar 9, 2026 | -$0.54 | -$0.46 | Beat |
| Nov 10, 2025 | -$0.53 | -$0.47 | Beat |
| Aug 6, 2025 | -$0.48 | -$0.57 | Miss |
| May 6, 2025 | -$0.35 | -$0.53 | Miss |